Skip to content

NIH NextTech R18 Guide 2026: Eligibility

Updated 7 official sources

Quick Answer: NIH NextTech R18 eligibility is strongest when a team has a diagnostic or therapeutic device that already passed proof-of-concept and now needs 4 kinds of translational work: optimization, safety evidence, regulatory-readiness work, and first-in-human planning.

Full answer and how we checked it

According to Simpler.Grants.gov, RFA-EB-26-004 lists $6,000,000 in program funding and 4 expected awards.

Who this is for: University device labs, translational engineering teams, small businesses with NIH partners, and research offices deciding whether a BRAIN or HEAL device project is ready for the NextTech R18 rather than an R01, R21, SBIR/STTR, or parent technology route.

Data note: This guide uses the forecasted NIH NextTech R18 opportunity (opens in a new tab), NIH BRAIN Initiative (opens in a new tab) and HEAL Initiative (opens in a new tab) source context, the live NextTech R18 program page, and Grantsights award-data signals checked on May 18, 2026. Status, the predecessor notice, and NIH RePORTER award records were rechecked on October 9, 2026.

In this guide

The NextTech R18 is not a general device grant. According to Simpler.Grants.gov (opens in a new tab), RFA-EB-26-004 is forecasted for NIH projects that move next-generation diagnostic and therapeutic devices toward readiness for first-in-human clinical trials. That makes the page valuable for a very specific searcher: a team that has real device progress but hasn't crossed into a clinical-trial application yet.

Use this guide with the live NextTech R18 program page, then compare it with NIH R01, R21, R03, and K awards, NIH grants complete guide, how to read a NOFO, and how grant reviewers score applications. Device teams can lose a full cycle by treating a translational NOFO like a science hypothesis grant. The strongest NextTech concepts make the device readiness question impossible to separate from the BRAIN or HEAL mission need.

NIH NextTech R18 Eligibility: 5 Stop Checks

5 stop checks should be passed before the team writes. According to Simpler.Grants.gov, eligible applicants include higher education, nonprofits, for-profits, governments, tribes, and non-U.S. entities. Eligibility is broad, but fit is narrow.

Stop checkStrong NextTech signalWeak signal
Mission fitDevice addresses a BRAIN or HEAL disorder or research needDisease area is outside both programs
Translation stageProof-of-concept exists and the bottleneck is readinessProject is still basic discovery
Device roleDiagnostic or therapeutic device changes a future clinical decisionTool is a generic platform without a near use case
Trial statusWork prepares for first-in-human reviewTeam wants to run a clinical trial now
Evidence planSafety, performance, usability, and pre-human approval studies are namedAims are broad optimization tasks

The common mistake is assuming "device" is enough. It isn't. RFA-EB-26-004 is looking for a device-development bridge. If the project still asks whether the core technology works at all, R21, R01, or SBIR Phase I may be the more honest route. If the project is already a human trial, this opportunity is also the wrong page.

Get research funding calls by email

About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.

No spam. Unsubscribe anytime.

Funding, Timing, and Award Math: $6M, 4 Awards, 2027 Start

$6,000,000 is the listed program funding, and Simpler.Grants.gov lists 4 expected awards. The same listing gave an estimated post date of July 17, 2026 and an estimated application due date of September 18, 2026, both now passed; it also listed an estimated award date of June 18, 2027 and an estimated project start date of July 18, 2027. When Grants.gov was rechecked on October 9, 2026, the record was still a forecast with no posted NOFO, so those estimated dates have slipped. The forecast names NIBIB program officers as the contact at NIBIB_Devices@NIH.gov.

FactSource-backed read
Opportunity numberRFA-EB-26-004
StatusStill a forecast on Grants.gov as of October 9, 2026
Expected awards4
Program funding$6,000,000
Cost shareNo
Clinical trial statusNot allowed

According to USAspending.gov (opens in a new tab) data, assistance listing 93.286 had about $343.8M in FY2024 obligations across 1,790 awards active that year. That family size is useful market context, not a promise that NextTech will be easy. Use the funding signal to understand demand, then use the NOFO to decide whether this exact mechanism fits.

What the Earlier HEAL Device R18 Funded (RFA-EB-22-002)

NextTech has a direct predecessor. RFA-EB-22-002 (opens in a new tab), "HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices," used the same R18 activity code and the same first-in-human readiness language, but it was limited to pain and opioid use disorder. NIH ended it early: NOT-EB-25-001 (opens in a new tab) canceled the final receipt date, moving expiration from June 18, 2025 to April 16, 2025. The 2026 forecast widens the mission to BRAIN as well as HEAL, so treat the older notice as a preview of how NIBIB has run this mechanism, not as the rules for RFA-EB-26-004.

According to NIH RePORTER (opens in a new tab) records pulled October 9, 2026, RFA-EB-22-002 produced 7 new R18 awards, all administered by NIBIB:

AwardRecipientDevice focusTotal awardProject period
1R18EB035004-01Duke UniversityPoint-of-care diagnostic for sickle cell disease$1,222,1222023-2027
1R18EB035005-01Stanford UniversityFocused ultrasound for noninvasive peripheral nerve block$2,505,5372023-2026
1R18EB035019-01University of VirginiaPhysiomarkers to assess neonatal opioid withdrawal$3,149,7002023-2026
1R18EB036591-01Massachusetts General HospitalTransspinal magnetic stimulation for neuropathic pain$3,565,7802024-2027
1R18EB037603-01University of ConnecticutImplantable, degradable non-opioid drug delivery for post-surgical pain$2,668,3012025-2028
1R18EB037604-01University of ConnecticutImplantable neuromodulation system for chronic pain$3,473,6162025-2028
1R18EB037607-01Columbia University Health SciencesDisplacement-guided focused ultrasound for pain$3,220,0272025-2028

The pattern is clear in those records. Every recipient was a university or academic medical center, every project was a specific device with a named clinical use, and each award was obligated in one lump for a 3- to 4-year period rather than in yearly increments. For example, Massachusetts General Hospital received $3,565,780 in FY2024 for a project running to August 2027. That matters for planning: if NextTech follows the same approach, a single award could carry the full project budget from day one.

What the 2022 Notice Required (A Preview, Not the New Rules)

The predecessor notice set terms device teams should expect to see again, though the final NextTech NOFO can change any of them:

  • Budget and length: budgets weren't capped but "should rarely exceed $750,000 direct cost per year," with up to 3 years of support.
  • Required work: a prototype intended for a future clinical study, plus a required 1-page Gantt chart. Missing either got an application withdrawn.
  • Optional attachments that carried weight: a needs assessment (3 pages), IACUC feedback (3 pages), and an IP strategy (2 pages).
  • Non-responsive work: hypothesis-driven studies, new animal models, biomarkers, small molecules or biologics, and any drug that isn't already FDA-approved for the indication.
  • Industry partners: letters of support from every industrial partner were required, with signed agreements before award.
  • Timeline test: a credible path to clinical use within 5 years and commercialization within 10.

Reviewers also got added questions: how big an advantage the device offers over clinically available options, how strong the rationale for the biological target is, and whether the team has enough regulatory, manufacturing, and commercialization experience to reach human use within 5 years. A team that can't answer those three questions today isn't ready for the new round either.

NextTech R18 vs R01, R21, SBIR/STTR, and Device-Specific Routes

6 route choices often sit near NextTech R18. The wrong choice changes the story reviewers receive. If the team needs to prove the core idea, an R21 or R01 may be cleaner. If a company owns the device path and commercialization is central, SBIR/STTR may deserve the first read. If first-in-human preparation is the bottleneck, NextTech becomes more interesting.

RouteBetter first read when...Why it may beat NextTech
NextTech R18Device has proof-of-concept and needs readiness workProgram intent matches the translational gap
Parent R01Main question is biological or mechanisticReview can focus on science rather than device readiness
R21Device concept is early and riskySmaller scope may fit the evidence level
SBIR/STTRSmall business owns the commercial pathProduct risk and company milestones are part of the logic
BRG R01Bioengineering method and biomedical problem are joinedBetter for research-project scale method work
Institute-specific NOFOOne institute has a narrow device priorityMore direct program fit

For the broader NIH route choice, compare NIH R01, R21, R03, and K awards. If the project is more like a bioengineering research project than a first-in-human readiness bridge, use the NIH BRG R01 guide. If the applicant is a company, pair this page with how to write an SBIR proposal before spending a month on the wrong mechanism.

What NIH Doesn't Tell You

4 facts in the official listing matter, but the listing does not make the applicant decision for you. It says NextTech supports development and translation of new devices for NIH BRAIN and HEAL mission areas. It says the work can include optimization and studies to prepare for approvals for human use. It says the clinical trial is not allowed. It does not tell you whether your device is ready enough.

First, NIH doesn't grade your readiness stage before submission. A team can have impressive engineering talent while the application is still asking whether the device can work at all. That is not a readiness bridge. That is a discovery project.

Second, NIH doesn't compare NextTech against SBIR/STTR for a small business. A company can be eligible and still be better served by a route that rewards commercialization planning, customer discovery, and later product milestones.

Third, NIH doesn't solve the BRAIN and HEAL boundary question. For implanted human recording work, compare the BRAIN invasive neural recording R61 guide. According to NIH, the BRAIN Initiative (opens in a new tab) funds neuroscience tool and brain-circuit priorities, while HEAL (opens in a new tab) is tied to pain and opioid-related research needs. A device that does not clearly sit in one of those lanes may be eligible on paper but weak in review.

Fourth, NIH doesn't tell you how reviewers will read "first-in-human readiness." The phrase has teeth. If the plan does not include safety, performance, usability, regulatory logic, and a credible next trial path, the application can look underbuilt.

5 Real-World NextTech Scenarios

5 scenarios show where the route decision changes. For example, a team with an implantable neuromodulation device for a pain condition could have a strong NextTech case if animal safety, device optimization, and first-in-human planning are the next bottlenecks. A lab building a new sensor for basic brain mapping would usually fit an R01 or BRAIN tool-development route better, such as the BRAIN BBQS sensor U01.

ScenarioBetter routeReason
Device has proof-of-concept and needs pre-human studiesNextTech R18Readiness is the center of the project
Core device function is unprovenR21 or R01Discovery risk comes first
Startup needs market and product milestonesSBIR/STTRCompany path is central
Existing clinical device is used in a disease studyParent R01Device development is not the main work
Late-stage intervention trialOther clinical-trial routeNextTech does not allow clinical trials

A company with a diagnostic device that already has animal and bench data, plus a clear BRAIN-related use case, should read NextTech seriously. A clinical group that wants to test an existing device in patients next quarter shouldn't try to squeeze a clinical trial into a no-trial R18.

7 Draft Checks to Run First

7 checks can prevent a weak submission. The strongest drafts answer the route-fit question on page 1.

  1. The device is named, not hidden behind general technology language.
  2. The BRAIN or HEAL mission fit is direct.
  3. Proof-of-concept data exists.
  4. The next bottleneck is first-in-human readiness.
  5. The work is not a clinical trial.
  6. Regulatory, safety, performance, and usability work are visible.
  7. The route has been compared against R01, R21, SBIR/STTR, and BRG.

According to USASpending.gov data, the connected family had about $343.8M in FY2024 obligations across 1,790 awards active that year. According to Simpler.Grants.gov, this specific opportunity lists $6,000,000 and 4 expected awards. Those 2 facts belong together: there is a large NIH technology funding base, but this R18 still has a narrow job.

Sources

Frequently Asked Questions

Who is the NIH NextTech R18 for?

The NIH NextTech R18 is for teams moving next-generation diagnostic or therapeutic devices toward first-in-human readiness for disorders in the NIH BRAIN and HEAL mission areas.

Is the NIH NextTech R18 open now?

Not yet. As of October 9, 2026, Grants.gov still lists NextTech R18 as a forecast. The forecast gave an estimated post date of July 17, 2026 and an estimated application due date of September 18, 2026, both now in the past, and no formal NOFO had posted. Check Grants.gov and the NIH Guide before planning around a date.

How much funding is listed for NextTech R18?

Simpler.Grants.gov lists $6,000,000 in program funding and 4 expected awards for RFA-EB-26-004.

Does NextTech R18 allow clinical trials?

No. The listed opportunity is R18 Clinical Trial Not Allowed. Teams should frame pre-human approval studies, optimization, and readiness work rather than a clinical trial.

Who should skip NextTech R18?

Skip it if the device is still basic discovery, if the project is mainly a conventional treatment trial, or if the disease area is outside BRAIN and HEAL priorities.

Last updated October 9, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.